INTRODUCTION: The latest WHO guidelines recommend initiating antiretroviral therapy (ART) at CD4 cell counts less than 350 cells/μl. However, donors and national governments are reluctant to support implementation owing to uncertainty regarding feasibility and relative benefit. Lesotho has supported earlier initiation since 2008. We assessed outcomes comparing early (CD4 cell counts >200 cells/μl) and late (CD4 cell counts ≤200 cells/μl) initiation. METHODS: We describe survival probability among patients initiating ART at CD4 cell counts 200 or less and more than 200 cells/μl and assess associations between baseline CD4 cell counts and mortality, morbidity, loss to follow-up and hospitalization using Cox regression adjusting for confounders identified a priori. RESULTS: Our analysis included 1177 patients; median age was 38 years and the majority (67%) were women. Median time on ART for the overall cohort was 506 days (interquartile range 396-608). Five hundred and thirty eight patients initiated ART at a CD4 cell count 200 cells/μl or less (interquartile range 54-160) and 639 patients initiated at CD4 cell count more than 200 cells/μl (interquartile range 238-321). In multivariate analysis, we found that patients initiating at CD4 cell count more than 200 cells/μl were 68% less likely to die (adjusted hazard ratio 0.32, 95% confidence interval 0.20-0.50), and 39% less likely to be lost to follow-up (adjusted hazard ratio 0.61, 95% confidence interval 0.43-0.87). Initiating ART at CD4 cell count more than 200 cells/μl was also associated with a 27% reduction in the rate of incident morbidity (adjusted hazard ratio 0.73, 95% confidence interval 0.65-0.82) and a 63% decreased rate of hospitalization (adjusted hazard ratio 0.37, 95% confidence interval 0.19-0.73). CONCLUSION: Earlier initiation is feasible in a low resource, high HIV prevalence setting, and provides important benefits in terms of reduced mortality, morbidity, retention and hospitalization. Donors should fully support the implementation of the latest WHO recommendations.
INTRODUCTION: The latest WHO guidelines recommend initiating antiretroviral therapy (ART) at CD4 cell counts less than 350 cells/μl. However, donors and national governments are reluctant to support implementation owing to uncertainty regarding feasibility and relative benefit. Lesotho has supported earlier initiation since 2008. We assessed outcomes comparing early (CD4 cell counts >200 cells/μl) and late (CD4 cell counts ≤200 cells/μl) initiation. METHODS: We describe survival probability among patients initiating ART at CD4 cell counts 200 or less and more than 200 cells/μl and assess associations between baseline CD4 cell counts and mortality, morbidity, loss to follow-up and hospitalization using Cox regression adjusting for confounders identified a priori. RESULTS: Our analysis included 1177 patients; median age was 38 years and the majority (67%) were women. Median time on ART for the overall cohort was 506 days (interquartile range 396-608). Five hundred and thirty eight patients initiated ART at a CD4 cell count 200 cells/μl or less (interquartile range 54-160) and 639 patients initiated at CD4 cell count more than 200 cells/μl (interquartile range 238-321). In multivariate analysis, we found that patients initiating at CD4 cell count more than 200 cells/μl were 68% less likely to die (adjusted hazard ratio 0.32, 95% confidence interval 0.20-0.50), and 39% less likely to be lost to follow-up (adjusted hazard ratio 0.61, 95% confidence interval 0.43-0.87). Initiating ART at CD4 cell count more than 200 cells/μl was also associated with a 27% reduction in the rate of incident morbidity (adjusted hazard ratio 0.73, 95% confidence interval 0.65-0.82) and a 63% decreased rate of hospitalization (adjusted hazard ratio 0.37, 95% confidence interval 0.19-0.73). CONCLUSION: Earlier initiation is feasible in a low resource, high HIV prevalence setting, and provides important benefits in terms of reduced mortality, morbidity, retention and hospitalization. Donors should fully support the implementation of the latest WHO recommendations.
Authors: Kate Clouse; Audrey Pettifor; Mhairi Maskew; Jean Bassett; Annelies Van Rie; Cynthia Gay; Frieda Behets; Ian Sanne; Matthew P Fox Journal: AIDS Date: 2013-02-20 Impact factor: 4.177
Authors: Nicole L De La Mata; Penh S Ly; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Jeremy Ross; Matthew G Law; Oon T Ng Journal: J Acquir Immune Defic Syndr Date: 2017-04-15 Impact factor: 3.731
Authors: Abigail M Hatcher; Janet M Turan; Hannah H Leslie; Lucy W Kanya; Zachary Kwena; Malory O Johnson; Starley B Shade; Elizabeth A Bukusi; Alexandre Doyen; Craig R Cohen Journal: AIDS Behav Date: 2012-07
Authors: Maria Lahuerta; Frances Ue; Susie Hoffman; Batya Elul; Sarah Gorrell Kulkarni; Yingfeng Wu; Harriet Nuwagaba-Biribonwoha; Robert H Remien; Wafaa El Sadr; Denis Nash Journal: J Health Care Poor Underserved Date: 2013-02
Authors: Paul K Drain; Elena Losina; Sharon M Coleman; Laura Bogart; Janet Giddy; Douglas Ross; Jeffrey N Katz; Ingrid V Bassett Journal: AIDS Care Date: 2015-07-25
Authors: Anna Grimsrud; Morna Cornell; Michael Schomaker; Matthew P Fox; Catherine Orrell; Hans Prozesky; Kathryn Stinson; Frank Tanser; Matthias Egger; Landon Myer Journal: J Epidemiol Community Health Date: 2015-12-23 Impact factor: 3.710
Authors: Mia L van der Kop; David I Ojakaa; Anik Patel; Lehana Thabane; Koki Kinagwi; Anna Mia Ekström; Kirsten Smillie; Sarah Karanja; Patricia Awiti; Edward Mills; Carlo Marra; Lennie Bazira Kyomuhangi; Richard T Lester Journal: BMJ Open Date: 2013-06-20 Impact factor: 2.692
Authors: Sharon Tsui; Caitlin E Kennedy; Lawrence H Moulton; Larry W Chang; Jason E Farley; Kwasi Torpey; Eric van Praag; Olivier Koole; Nathan Ford; Fred Wabwire-Mangen; Julie A Denison Journal: Trop Med Int Health Date: 2021-08-08 Impact factor: 2.622
Authors: Katharina Kranzer; Darshini Govindasamy; Nathan Ford; Victoria Johnston; Stephen D Lawn Journal: J Int AIDS Soc Date: 2012-11-19 Impact factor: 5.396